Hypertriglyceridemia, but not hypercholesterolemia, is associated with the alterations of fibrinolytic system

Hormone and Metabolic Research

Volumn 28, Issue 11, 1996, Pages 603-606

  Hiraga, T ^a   Shimada, M ^a   Tsukada, T ^a   Murase, T ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Antigen; Fibrinolysis; Hypertriglyceridemia; Plasma plasminogen activator inhibitor 1; Plasma tissue type plasminogen activator antigen

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS;

EID: 0029855894     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979862     Document Type: Article

References (14)

1. Avellone, G., V. Di Garbo, R. Cordova, G. Raneli, R. De Simone, G. D. Bumpiani: Fibrinolysis in hypertriglyceridemic subjects in response to venous occlusion. Blood Coagul. Fibrinolysis 4: 429-433 (1993)
2. Beaumont, T., A. Carlson, R. Cooper, Z. Fajfar, S. Fredrickson, T. Strasser: Classification of hyperlipidemias and hyperlipoproteinemias. Bull. WHO 43: 891-908 (1970)
3. Bergsdorf, N., T. Nilsson, P. Wallen: An enzyme linked immunosorbent assay for determination of tissue plasmonogen activator applied to patients with thromboembolic disease. Thromb. Haem. 50: 740-744 (1983)
4. Castelli, W., R. Garrison, P. Wilson, R. Abbott, S. Kalousdian, W. Kannel: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256: 2835-2838 (1986)
5. Declerck, P., M. Alessi, M. Verstreken, E. Kruithof, I. Juhan-Vague, D. Collen: Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 71: 220-225 (1988)
6. Friberger, P., M. Knos, S. Gustavsson, L Aurell, G. Claeson: Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis 7: 138-145 (1978)
7. Hamsten, A., B. Wiman, U. de Faire, M. Blomback: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N. Engl. J. Med. 313: 1557-1563 (1985)
8. Hamsten, A., U. de Faire, G. Walldius, G. Dahlen, A. Szamosi, C. Landou, M. Blomback, B. Wiman: Plasminogen Activator Inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 8549: 3-8 (1987)
9. Huber, K., I. Resch, Th. Stetenelli, I. Lang, P. Probst, F. Kaindl, B. R. Binder: Plasminogen activator inhibitor-1 levels in patients with chronic angina pectoris with or without angiographic evidence of coronary sclerosis. Thromb. Haemost. 63: 336-339 (1990)
10. Reaven, G. M.: Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607 (1988)
11. Ridker, P. M., D. E. Vaughan, M. J. Stampfer, J. E. Manson, C. H. Hennekens: Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 341: 1165-1168 (1993)
12. Ridker, P. M., C. H. Hennekens, M. J. Stampfer, J. E. Manson, D. E. Vaughan: Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 343: 940-943 (1994)
13. Steinmetz, A.: Phenotyping of human apolipoprotein E from whole blood plasma by immunoblotting. J. Lipid Res. 28: 1364-1370 (1987)
14. Takahashi, H., M. Hanano, S. Takizawa, W. Tatewaki, A. Shibata: Plasmin-α2 plasmin inhibitor complex in plasma of patients with disseminated intravascular coagulation. Am. J. Hematol. 28: 162-166 (1988)